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CD4Vpu is a small membrane protein encoded by HIV-1 and some SIV isolates. The protein is best known for its
ability to degrade CD4 and to enhance the release of progeny virions from infected cells. However, Vpu also
promotes host-cell apoptosis by deregulating the NFκB signaling pathway and it assembles into cation-
conducting membrane pores. This review summarizes our current understanding of these various functions
of Vpu with particular emphasis on recent progress in the Vpu ﬁeld. This article is part of a Special Issue
entitled: Viral Membrane Proteins — Channels for Cellular Networking.
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Viruses face a variety of obstacles when infecting a new host. Of
particular importance is the host innate immune system that can
form a potent barrier to viral infections. Viruses have adapted toembrane Proteins — Channels
.V.this challenge in a variety of ways. Primate lentiviruses, including
HIV-1, have acquired several genes whose primary if not exclusive
function is to neutralize host innate immune defense mechanisms
(for review see Refs. [1,2]). Vpu is an accessory protein unique to
HIV-1 and its predecessor SIV strains. The initial functional property
attributed to Vpu was to facilitate virus release from infected cells
[3,4]. It became apparent early on that this function of Vpu was host
cell-dependent [5,6], suggesting the involvement of host cell factor(s).
This observation was further supported by experiments involving
heterokaryon analyses [7]. However, not until 20 years after the initial
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BST-2 unraveled [8,9]. Prior to the identiﬁcation of BST-2, different func-
tional models of how Vpu regulates virus release had been proposed.
These included a correlation of enhanced virus release with a Vpu ion
channel activity or with the inactivation of a cellular background chan-
nel, TASK-1 [10–12]. However, the identiﬁcation of BST-2 as an
interferon-inducible host factor whose expression induced a severe
but Vpu-sensitive restriction of virus release caused a major shift in re-
search focus andmade the earliermodels fade into the background. It is
fair to say that the identiﬁcation of BST-2 and its effect on virus release
has been a major advance in the ﬁeld and investigating the role of Vpu
in the antagonism of BST-2 is currently the most active aspect of
Vpu-related research. Nevertheless, one should not ignore the fact
that Vpu controls additional functions. These include degradation of
the HIV-receptor CD4 or the inhibition of NFκB activation. These func-
tions of Vpu are mechanistically relatively well understood although
their functional signiﬁcance for HIV replication is still under discussion.
The purpose of this review is to provide a brief update on our current
understanding of the role of Vpu in regulating virus release and to dis-
cuss its other known functions and their potential impact on virus
replication2. Functional properties of HIV-1 Vpu
2.1. Vpu induces degradation of CD4
The Vpu open reading frame is located upstream of and overlapping
the viral env gene. Interestingly, Vpu and the envelope precursor glyco-
protein, gpl60, are expressed from a single bicistronic mRNA while all
otherHIV products are produced froma complex pattern of differentially
spliced mRNAs or via the proteolytic processing of the Gag and Gag-Pol
polyproteins. This unusual utilization of viral transcripts suggested a
requirement for the coordinate action of Vpu and Env. Indeed, it was
known at the time that CD4, the receptor for HIV-1 had a propensity to
interact with gpl60 in the endoplasmic reticulum (ER), resulting in the
accumulation of trafﬁcking-incompetent complexes of CD4 and Env
in the ER [13–15]. This led to the investigation of a possible role of Vpu
in the dissociation of such Env-CD4 complexes and the subsequent
identiﬁcation of Vpu-induced degradation of CD4 [16,17]. Indeed, in
Vpu-expressing cells, de novo synthesized CD4 is rapidly degraded in
the ER reducing its normal half-life of about 6 h to approximately
15 min (for review see Ref. [18]). It is well accepted that ER-associated
degradation of CD4 by Vpu requires a physical interaction of the cyto-
plasmic domains of the two proteins that in CD4 has been mapped to a
short membrane-proximal motif [19–23] and in Vpu was more recently
shown to involve both cytoplasmicα-helices [24] (Fig. 1A). Some groups
reported an additional contribution of the transmembrane (TM) do-
mains of CD4 and Vpu as prerequisite for CD4 degradation [25–27]. Of
particular interest is the observation that a conserved tryptophan
residue (W22) in the Vpu TM domain, when mutated to leucine
(W22L) did not prevent Vpu–CD4 interaction but almost completely
abolished Vpu-induced degradation of CD4 [27]. This ﬁnding is intrigu-
ing as it implies a contribution of theVpu TMdomain to CD4 degradation
that goes beyond the mere stabilization of Vpu–CD4 complexes. Other
reports, however, demonstrated that replacing the TM domain of CD4
by that of CD8 [28] or scrambling the sequence of the Vpu TM domain,
which included a repositioning ofW22 [29] had no impact on the ability
of Vpu to induce CD4 degradation. Furthermore, replacing the entire Vpu
TM domain by TM domains from heterologous transmembrane proteins
did not affect the ability of Vpu to induce CD4 degradation ([30] and
Strebel, unpublished). It is unclear why an individual amino acid change
in the Vpu TM domain has amore drastic effect than global replacement
of the entire TM domain in either Vpu or CD4. However, structural
changes in the membrane helix are a likely cause. It is conceivable that
relatively non-speciﬁc interactions between the hydrophobicmembranehelices of CD4 and Vpu or its chimeras stabilize Vpu–CD4 interactions
and contribute to Vpu-induced CD4 degradation.
Aside from sequences required for the physical interaction of
Vpu and CD4, a conserved di-phosphoserine motif located between
the two cytoplasmic α-helices in Vpu is critical for the assembly of a
β-TrCP-containing SKP1, Cullin, F-box protein (SCF) E3 ubiquitin ligase
complex (SCFTrCP) [31] that ultimately leads to the ubiquitination of
CD4 followed by proteasomal degradation (reviewed in [18,32]
(Fig. 1A). The role of the Vpu phosphoserine residues in the induction
of CD4 degradation became apparent when yeast two-hybrid assays
as well as coimmunoprecipitation studies revealed an interaction of
Vpu with human β-TrCP [31]. The interaction of Vpu with β-TrCP
leads to the assembly of a ubiquitin ligase complex that targets the
cytoplasmic domain of CD4 [31,33,34]. Interestingly, Vpu itself is not
ubiquitinated in the process and therefore assumes the role of an inert
adapter molecule. This characteristic of Vpu likely accounts for the
effect of Vpu on NFκB deregulation described below. The cytoplasmic
domain of CD4 contains four lysine residues as potential targets
for ubiquitination. Interestingly, mutation of all four lysines neither
abolished Vpu-induced CD4 ubiquitination nor did it prevent
Vpu-induced degradation [33]. An explanation for this phenomenon
may be provided by the recent observation that degradation of CD4
by Vpu may involve not only ubiquitination of lysines but also serine/
threonine residues in its cytoplasmic domain [34].
2.2. Vpu regulates detachment of virions
2.2.1. BST-2 inhibits virus release
Recent efforts in the Vpu ﬁeld have almost exclusively focused on
understanding its role in regulating virus release. It is now generally
accepted that the regulation of virus release by Vpu involves the func-
tional inactivation of BST-2 (also known as CD317, HM1.24, or
tetherin). BST-2 was originally identiﬁed as a cellular transmembrane
protein in terminally differentiated human B cells of patients with
multiple myeloma [35,36] and was later identiﬁed as the host factor
responsible for the Vpu-sensitive inhibition of virus particle release
[8,9]. BST-2 was identiﬁed as a target for Vpu already two years earlier
in a proteomics study that also identiﬁed the Kaposi sarcoma-associated
herpesvirus K5 protein as a BST-2 antagonist. In fact, both Vpu and K5
when overexpressed in HeLa cells reduced the levels of endogenous
BST-2 [37].
2.2.2. Structural considerations
BST-2 is a 30–36 kDa type II transmembrane glycoprotein
consisting of 180 amino acids [38]. Rat BST-2 is predicted to have an
N-terminal transmembrane (TM) region and a C-terminal glycosyl-
phosphatidylinositol (GPI) anchor [39]. However, recent evidence
suggests that the C-terminal membrane anchor, at least in human
BST-2, could be a second transmembrane domain rather than a GPI
anchor [40]. The two TM domains are separated by approximately
120 residues that constitute the protein's ectodomain, which is pre-
dicted to form a rod-like α-helical structure of about 16–17 nm
[41–44]. The BST-2 ectodomain contains two N-linked carbohydrates
[35,39,45,46] whose functional importance is not clear [45,46]. Three
cysteine residues in the BST-2 ectodomain contribute to the forma-
tion of covalently linked dimers [35,36,45,46]. Interestingly, only
one cysteine residue is necessary and any one of the three cysteine
residues is sufﬁcient for the assembly of BST-2 into functional cova-
lently linked dimers [45,46].
A current model suggests that BST-2 tethers mature virions to the
cell surface by means of its N- and C-terminal TM domains. Interest-
ingly, artiﬁcial BST-2 consisting of the N-terminal TM region of trans-
ferrin receptor, a coiled-coil ectodomain of the cytoplasmic dimeric
protein dystrophia myotonica protein kinase, and a GPI anchor signal
derived from urokinase plasminogen activator receptor was capable
of inhibiting the release of HIV-1 virions tethered to the cell surface
Fig. 1. CD4 degradation and deregulation of the NFkB pathway involve Vpu-β-TrCP interactions. (A) Vpu can bind newly synthesized CD4 in the endoplasmic reticulum (ER)
through interactions mediated by the cytoplasmic helices as well as the transmembrane (TM) helices. The role of W22 in the Vpu TM helix is discussed in the text (Section
2.1.). Vpu is constitutively phosphorylated at serines 52 and 56. This motif constitutes a binding motif for β-TrCP and leads to the assembly of an E3–Ub ligase complex that results
in ubiquitination and proteasomal degradation of CD4. (B) NFkB resides in the cytoplasm in an inactive form bound to its inhibitor IkB. Upon receptor stimulation, IkB is phosphor-
ylated and degraded following β-TrCP induced ubiquitination. This releases NFkB, which then trafﬁcs to the nucleus and activates gene transcription. Deregulation of the NFkB path-
way by Vpu is due to the competitive binding of β-TrCP. Unlike IκB, Vpu is not degraded upon binding to β-TrCP. This leads to a depletion of free β-TrCP in the cell and inhibition of
NFkB activation following receptor stimulation.
1076 K. Strebel / Biochimica et Biophysica Acta 1838 (2014) 1074–1081[46]. This suggests that secondary structure rather than primary
amino acid sequence of BST-2 is important for tethering function.
This conclusion is supported by the observation that alanine scanning
across much of the ectodomain failed to affect BST-2 function [47]
and there is signiﬁcant ﬂexibility in the size of the BST-2 ectodomain
[48]. Extending or substituting the BST-2 ectodomain using a heterol-
ogous coiled-coil motif maintained tethering function [48]. In fact,
adding heterologous coiled-coil sequences to the existing BST-2
coil-coil thereby almost doubling the size of the BST-2 ectodomain
had no impact on BST-2 function [48]. Conversely, approximately
half of the ectodomain, including a block of seven heptad motifs
believed to be important for coiled-coil formation, could be deleted
without losing tethering function. Taken together, these data indicate
that the size and primary sequence of the BST-2 ectodomain can be
altered to a signiﬁcant degree without loss of function.
Electron microscopic images not only revealed vpu-defective
virions tethered to the cell surface; in many instances, virus particles
appear to be tethered to each other [8,49,50]. If BST-2 wereresponsible for the formation of virus aggregates, it would be
expected that BST-2 is present in such virions. Indeed, defective
BST-2 variants lacking either N- or C-terminal TM domain were read-
ily detected in cell-free virus preparations [46] suggesting that BST-2
is not actively excluded from virions. Interestingly, immune-electron
microscopy identiﬁed the presence of wild type BST-2 in both wild
type and Vpu-defective virions [51,52] and similar results were
obtained using a bead-based virion capture assay [52]. Furthermore, im-
munoblot analysis of concentrated virus preparations revealed the
presence of BST-2 in both wild type and Vpu-defective virions. Indeed,
Vpu-defective virions contained signiﬁcantly higher levels of BST-2
than wild type virus, when normalized for capsid levels [52]. This result
is surprising if one accepts the popular tetheringmodel of BST-2, which
proposes that BST-2 physically tethers virions to the virus-producing
cell. If one assumes that the association of BST-2 with nascent virions
follows a Gaussian distribution model, one might predict that even in
the absence of Vpu, a certain fraction of virions will be spontaneously
released due to insufﬁcient levels of BST-2 associatedwith these virions.
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should be lower than or equal to that observed in wild type virions but
certainly not higher. Consistent with that we found that preparations of
vpu-defective virions that had been removed from BST-2 positive HeLa
cells by physical force lacked detectable levels of BST-2 [53]. While the
reasons for this apparent discrepancy remain unclear, it is fair to say
that endogenous wild type BST-2 is packaged into both wild type and
Vpu-defective HIV-1 virions at levels that are not inhibitory.2.2.3. How does Vpu antagonize BST-2?
While Vpu expression ultimately leads to the cell-surface down-
modulation of BST-2 [9,53–59], we found that in productively infected
T cell cultures, Vpu can antagonize BST-2 to yield efﬁcient virus release
without apparent effect on its cell surface expression [53]. Similar obser-
vations were reported for the antagonism of BST-2 by the Ebola virus
glycoprotein [60]. This raises the question of how it is possible that the
tethering activity of BST-2 can be inhibited without removal of the
protein from the cell surface. One possible solution is that Vpu and/or
Ebola glycoprotein alter the surface distribution of BST-2, which is
normally associatedwithmembrane raft structures [39,40,60–64]. How-
ever, Lopez et al failed to see an effect of Vpu or Ebola glycoprotein on
BST-2's distribution within lipid rafts [60]. BST-2 rapidly cycles between
the cell surface and internal membranes [56,58,65] (Fig. 2; (1)); howev-
er, Vpu does not increase the rate of BST-2 internalization but rather
seems to affect the resupply of newly synthesized BST-2 to the cell
surface [65,66] (Fig. 2; (4)). Such a function could be exerted from an in-
tracellular location such as the trans-Golgi compartment. Vpu was also
found to reduce total cellular levels of endogenous aswell as exogenous-
ly expressed BST-2 [37,53,56,57,67,68]. How exactly this is accomplished
is still under debate and it is not clear yet whether the reduced BST-2
levels are a cause or consequence of BST-2 surface downmodulation.
Several studies reported the involvement of a proteasomal degradation
pathway [67] and suggested β-TrCP dependence [68]. In contrast, other
studies reported aβ-TrCP-dependent endo-lysosomal pathway to be im-
portant for degradation [56,57,59]. The involvement of β-TrCP in the
virus release activity of Vpu necessitates conservation of Vpu's TrCP
binding motif. However, mutation of this motif was previously foundFig. 2. Vpu antagonizes BST-2 by inhibiting the resupply of BST-2 from the ER. (1) Existing B
cycle a fraction of the protein is routed to lysosomes for degradation (2). Steady state levels
reticulum (ER; (3)). Vpu interferes with the resupply of surface BST-2 presumably by redirto only partially affect Vpu's virus release activity [9,69,70] and in more
recent studies expression of a TrCP-binding mutant of Vpu (Vpu26)
supported HIV replication with wild type kinetics in a variety of cell
types including PBMC [53]. Finally, expression of a β-TrCP binding-
deﬁcient Vpu26 mutant did not reduce total cellular BST-2 levels but,
to the contrary, appeared to stabilize or even increase BST-2 surface ex-
pression [53]. This phenomenon could explain the partial effect of Vpu26
on virus release, which could be the result of increased levels of BST-2
rather than partial antagonism of BST-2 by Vpu26. Importantly, degrada-
tion of BST-2 was not essential for Vpu to enhance virus release [53,71]
suggesting it may be a downstream consequence of the Vpu-induced
BST-2 surface downmodulation.2.2.5. BST-2: A host-restriction factor or a modulator of
viral dissemination?
BST-2 can be neutralized by three different lentiviral proteins:
HIV-1 employs Vpu, HIV-2 uses its Env glycoprotein, and SIV uses
Nef. All three proteins are either integral membrane proteins (Vpu,
Env) or are membrane-associated by means of a myristic acid modiﬁ-
cation (Nef) and are thought to interfere with BST-2 function via
direct physical interaction [55–59,68,72–85]. While their molecular
mechanisms of action may vary, the fact that lentiviruses have
evolved three proteins to independently target BST-2 highlights the
importance of controlling BST-2 function. It remains a matter of
debate however, exactly why control of BST-2 is of such importance
to HIV. The expression of BST-2 on human target cells has been
credited with the limited transmission of HIV-1 from its predecessor
SIV [86]. This is because Vpu from SIVcpz, while capable of degrading
CD4, is unable to target chimpanzee or human BST-2 [75]. In these
viruses, Nef has assumed the role of Vpu to enhance virus release.
However, Nef cannot target human BST-2 because its target sequence
(G/D)DIWK) located in the cytoplasmic domain of BST-2 has been lost
in human BST-2 more than 800,000 years ago [87]. It is not quite clear
how or even why Vpu acquired its anti-BST-2 activity. For instance
HIV-2, which lacks a vpu gene, has learned to use its Env glycoprotein
to antagonize human BST-2 [55,88–90]. Of note, even some HIV-1
isolates, such as the R5-tropic AD8 isolate, can make use of theirST-2 rapidly cycles between the cell surface and endocytic compartments. During each
of surface BST-2 are maintained by resupply of degraded BST-2 from the endoplasmic
ecting BST-2 directly to the endocytic/lysosomal compartment (4).
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interesting question of whether following the initial zoonosis, the Env
protein temporarily assumed Vpu-like function. At any rate, the abil-
ity to target BST-2 is not a feature of Vpu that arose only as a result of
the transmission of SIV into humans. Indeed, Vpus encoded by SIVgsn,
SIVmon, SIVmus, and SIVden are active against the BST-2 of their na-
tive hosts but not against human BST-2 [75,92].
Inhibition of virus release should not be mistaken for inhibition of
virus replication. Even though in short-term analyses, BST-2 seemed
to delay the cell-to-cell transmission of vpu-defective HIV-1 [93],
and even though BST-2 potently inhibited replication of Mo-MLV
in interferon-stimulated NIH 3T3 cells or in mice treated with
polyinosinic:polycytidylic acid, no difference in plasma viremia was
observed under physiological conditions between untreated normal
or BST-2 knockout MoMLV-infected mice [94]. Also, in long-term
multi-round replication analyses, the phenotype of a vpu defect
in HIV-1 was evident by reduced levels of cell-free virus but not by re-
duced viral replication kinetics [3,4]. This indicates that vpu-defective
virus can employ a cell-to-cell mode of transmission that, at least in
tissue culture, is as effective as cell-free transmission by wild type
virus. Thus, we prefer to look at BST-2 as a modulator of the mode
of viral transmission (i.e. cell-free versus cell-to-cell) rather than a
restriction factor inhibiting virus replication. If virus spread from
person to person occurs through transmission of cell-free virus, viruses
unable to target BST-2 will certainly have a selective disadvantage. On
the other hand, the fact that a number of HIV-1 isolates, including
HXB2, MAL, and AD8, carriedmutations in the vpu translation initiation
codon [95,96], suggests that Vpu expression may provide selective
advantages or disadvantages and may be turned on or off depending
on the environmental pressures provided by the host.
3. About ion channels and virus release
3.1. Vpu forms ion conductive membrane pores
Based on the structural similarity of Vpu with the inﬂuenza virus
M2 ion channel protein it was speculated that homo-oligomeric
complexes of Vpu might possess pore-forming abilities [97]. Indeed,
Vpu ion channel activity was experimentally demonstrated as current
ﬂuctuations across an artiﬁcial lipid bilayer containing either full-
length recombinant Vpu protein or synthetic peptides corresponding
to the cytoplasmic domain of Vpu [10,11,98,99]. The Vpu channel
activity is selective for monovalent cations such as sodium and potas-
sium. Of note, the channel activity of the Vpu TM domain was speciﬁc
as scrambling the sequence abolished channel activity [29]. This in-
triguing correlation between the ability of Vpu to form ion conductive
channels and to enhance viral particle release in vivo led to the
proposal that regulation of virus release by Vpu might involve an
alteration of the plasma membrane potential. This model was sup-
ported by the observation that membrane depolarization could affect
the rate of HIV-1 virus release [100] and that expression of Vpu in
yeast caused membrane depolarization resulting in cytotoxicity and
impaired cell growth, an effect that could be minimized by increasing
extracellular K(+) concentration [101]. Additional support for the ion
channel model of Vpu came from animal studies in which scrambling
the Vpu TM domain in the context of a SHIV virus signiﬁcantly re-
duced viral load and lowered viral pathogenicity [102]. Despite
all of that, exactly how ion channel activity of Vpu might regulate
viral particle production had remained unclear. Indeed, more recent
studies argue against an involvement of Vpu ion channel activity in
Vpu-enhanced virus release. These new ﬁndings are based on the
observation that some mutations in the Vpu TM domain affecting
channel activity (e.g. S23A or S23L) did not impair the ability to en-
hance virus release; conversely, somemutations affecting virus release
(e.g. A14N, A18N) retained ion channel activity [54,103–105]. Thus,
while there is no doubt that Vpu can assemble into ion conductingmembrane pores, the functional signiﬁcance of Vpu ion channel activity
for HIV replication remains unclear.
3.2. Vpu inhibits the cellular ion channel TASK-1
A different model for Vpu function was proposed by a study
suggesting that Vpu affects the activity of the mammalian background
K(+) channel TASK-1 [12]. The N-terminal domain of TASK-1 exhibits
signiﬁcant structural homology to Vpu. Indeed, Vpu was found to inter-
actwith TASK-1 and coexpression of Vpu inhibited the TASK-1 ion chan-
nel activity [12]. Also, coexpression of TASK-1 with the N-terminal
fragment exhibiting homology to Vpu (Ttm1) inhibited TASK-1 ion
channel function. Interestingly, expression of Ttm1 increased release of
Vpu-defective virus from HeLa cells to a similar extend than wt Vpu
[12]. Thus, it was proposed that TASK-1 was a cellular inhibitor of
virus release whose activity has to be neutralized by Vpu. If this were
true, one would expect that TASK-1 is expressed in non-permissive
cell types such as HeLa or Jurkat but is absent in permissive cells,
e.g. Cos-7 or 293T. This has not been observed, however. Alternatively,
one could argue that TASK-1 itself functions in a cell-type independent
manner but indirectly regulates virus release by affecting BST-2 func-
tion. At this point, there is, however, no experimental evidence for
such a function of TASK-1. Thus, based on current knowledge BST-2 is
the sole contender for the role of regulator of viral particle release.
4. Other functions of Vpu
4.1. Vpu induces apoptosis by deregulating the NFkB pathway
As noted above (Section 2.1.), Vpu-induced degradation of CD4
involves the recruitment of β-TrCP via a conserved di-phosphoserine
motif in the Vpu cytoplasmic domain. Interestingly, the recognition
motif on all known cellular substrates ofβ-TrCP consists of a pair of con-
served phospho-serine residues similar to those present in Vpu [31].
Serine-phosphorylation plays the major regulatory role in the stability
of SCF target proteins. For example, activation of the IκB
kinase complex (IKK) by external stimuli such as TNFα induces the
serine-phosphorylation of IκBα followed by rapid TrCP-mediated
proteasomedegradation [106].More relevant to Vpu, BST-2was recently
shown to activate NFκB in a Vpu-sensitivemanner [107,108]. Intriguing-
ly, Vpu differs from normal cellular substrate of β-TrCP by its resistance
to proteasome degradation. Indeed, while the SCFTrCP usually degrades
the serine-phosphorylated protein directly bound to the β-TrCP WD
domains (i.e. Vpu), CD4 – bound to the Vpu cytoplasmic domain – is
degraded instead. This phenomenon has serious implications for the reg-
ulation and availability of the SCFTrCP in cells that express Vpu. Indeed,
due to the fact that Vpu is constitutively phosphorylated [109], binds
β-TrCP with high afﬁnity [31], and is not released from the complex by
degradation [110], Vpu expression in HIV-infected cells was likely to
perturb the physiological function of the SCFTrCP through competitive
trapping of β-TrCP (Fig. 1B). Indeed, the deregulation of IκB by Vpu
was shown to lead to inhibition of both HIV- and TNF-α-induced activa-
tion of NFκB [110]. The deregulation of NFκB in Vpu expressing cells has
far-reaching consequences since NFκB is a central transcription factor
that regulates the expression of key cellular genes involved in cell prolif-
eration, cytokine production and the induction of apoptosis [111,112].
Inhibition of NFκB activity by Vpu might therefore contribute to the
induction of apoptosis in HIV-1 infected cells [113,114]. This was con-
ﬁrmed experimentally by showing that in a population of Jurkat cells
expressing wild-type HIV-1, twice as many cells underwent apoptosis
than in cells infected with a Vpu-defective virus [115]. Mechanistically,
Vpu was shown to inhibit the NFκB-dependent expression of anti-
apoptotic genes such as Bcl-2 family proteins, leading to enhanced intra-
cellular levels of the apoptosis-promoting caspase-3 [115]. Active
caspase-3 then triggers a reaction that results in the cleavage of a
1079K. Strebel / Biochimica et Biophysica Acta 1838 (2014) 1074–1081number of target proteins including Bcl-2 family proteins and leads to
cell death [115].
4. Conclusions
The HIV-1 Vpu protein is a small transmembrane protein with
several independent functions that are controlled from different cel-
lular compartment. Degradation of CD4 occurs in the endoplasmic
reticulum and involves the ERAD pathway. Vpu's function is that of
a molecular adaptor that connects CD4 to the SCFTrCP E3 ubiquitin
ligase complex ultimately resulting in the degradation of CD4.
Sequences in the Vpu cytoplasmic domain are critical for this process
but a speciﬁc contribution of the TM domain is being proposed as
well. Enhanced virus release is accomplished by down-modulating
BST-2 from the cell surface. The precise mechanism of BST-2 antago-
nism by Vpu is not yet understood. However, the Vpu TM domain is
critical for this process to enable the physical association with
BST-2. Finally, Vpu deregulates the NFκB pathway due to two unusual
characteristics: (i) Vpu is constitutively phosphorylated and thus
capable of continuously binding β-TrCP; (ii) unlike normal cellular
substrates of β-TrCP, Vpu is not degraded as a result of β-TrCP
engagement and is thus capable of depleting the cellular pool of
free β-TrCP. Since β-TrCP is a critical regulator of the NFκB inhibitor
IκB, depletion of free β-TrCP prevents NFκB activation. Structurally,
Vpu assembles into homo-oligomeric complexes with the ability to
form ion conductive membrane pores. While regulation of virus
release by Vpu was initially attributed to ion channel activity, exper-
imental evidence no longer supports such a model. It is therefore
unclear at this point, which – if any – of the described functions of
Vpu require oligomerization of Vpu. Thus, while nothing has changed
on the fact that Vpu can form ion conducting membrane pores, its job
description remains undeﬁned.
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